| YNe | therapeutic agents d-out qh |
| HN | ETOH descriptor 2000. | |
| NT | +YPe anti-AOD-abuse agents qh ah | |
| +YQ anti-inflammatory, anti-infective, and antineoplastic agents qh ah | ||
| +YR analgesics and anesthetics qh ah | ||
| +YS reproductive control agents qh ah | ||
| +YTe agents used in body system disorders qh ah | ||
| RT | +EBe metabolism qh ah | |
| +EB10e drug metabolism qh ah | ||
| +EE14.4.4.2e therapeutic drug effect qh ah |
| YPe | anti-AOD-abuse agents d-out qh |
| SN | This section lists pharmacologic agents used in or tested for various facets of the treatment of AOD abuse, its causes, and its consequences. The section begins with a classification of treatment functions that is used throughout, keeping in mind that many of these treatment functions overlap and that many agents are used in multiple functions. The section then is organized by substance or substance class being abused. If the agent being discussed is used in treating abuse of a substance that does not fall into any of the substance classes, use the generic treatment function descriptor combined with the descriptor for the substance. | |
| ST | pharmacologic agents for AODD | |
| BT | +YNe therapeutic agents qh ah | |
| RT | +GCe AODD qh ah | |
| +HK2.10 AODD drug therapy qh ah |
| YP2 | . anti-AOD-abuse agents by function qh |
| HN | Introduced 1995. |
| YP2.2e | . . anti-AOD-intoxication agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| NT | +YP4.2e anti-alcohol-intoxication agents qh ah | |
| YP6.2 anti-sedative-hypnotic-intoxication agents qh ah | ||
| YP10.2 anti-cocaine-intoxication agents qh ah | ||
| +YP12.2 anti opiate intoxication agents qh ah |
| YP2.4e | . . AOD detoxification agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| NT | YP4.4e alcohol detoxification agents qh ah | |
| YP6.4 sedative-hypnotic detoxification agents qh ah | ||
| +YP8.4 nicotine detoxification agent qh ah | ||
| YP10.4 cocaine detoxification agents qh ah | ||
| +YP12.4 opiate detoxification agents qh ah |
| YP2.6e | . . AOD withdrawal agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| SN | Agents for the treatment of acute AOD withdrawal and its symptoms, including substances tested for alleviation of hangover. Protracted withdrawal may cause mental/psychiatric symptoms or lead to the reemergence of preexisting mental disorders that must be treated; see *+YP2.8.12 agents for AOD-concurrent mental disorders* qh ah. | |
| NT | +YP4.6e alcohol withdrawal agents qh ah | |
| +YP6.6 sedative-hypnotic withdrawal agents qh ah | ||
| YP8.6 nicotine withdrawal agents qh ah | ||
| YP10.6 cocaine withdrawal agents qh ah | ||
| +YP12.6 opiate withdrawal agents qh ah |
| YP2.8e | . . AOD relapse prevention agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| ST | AOD dependent maintenance agents | |
| NT | +YP4.8e alcohol relapse prevention agents qh ah | |
| +YP6.8 sedative-hypnotic relapse prevention agents qh ah | ||
| +YP8.8 nicotine relapse prevention agents qh ah | ||
| +YP10.8 cocaine relapse prevention agents qh ah | ||
| +YP12.8 opiate relapse prevention agents qh ah | ||
| YW6.2.2e tianeptine qh ah | ||
| RT | +AH20e AODD relapse qh ah |
| YP2.8.2e | . . . anti-AOD-craving agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| ST | anticraving agents | |
| NT | +YP4.8.2e anti-alcohol-craving agents qh ah | |
| YP6.8.2 anti-sedative-hypnotic-craving agents qh ah | ||
| YP8.8.2 anti-nicotine-craving agents qh ah | ||
| +YP10.8.2 anti-cocaine-craving agents qh ah | ||
| YP12.8.2 anti-opiate-craving agents qh ah |
| YP2.8.4 | . . . AOD agonist maintenance agents qh |
| HN | Introduced 1995. | |
| NT | YP4.8.4 alcohol agonist maintenance agents qh ah | |
| YP8.8.4 nicotine agonist maintenance agents qh ah | ||
| YP10.8.4 cocaine agonist maintenance agents qh ah | ||
| +YP12.8.4 opiate agonist maintenance agents qh ah |
| YP2.8.6 | . . . AOD blockers qh |
| HN | Introduced 1995. | |
| ST | AOD antagonists | |
| NT | +YP4.8.6e alcohol blockers qh ah | |
| YP6.8.4 sedative-hypnotic blockers qh ah | ||
| +YP8.8.6 nicotine blockers qh ah | ||
| +YP10.8.6 cocaine blockers qh ah | ||
| +YP12.8.6 opiate blockers qh ah |
| YP2.8.8 | . . . AOD deterrents qh |
| HN | Introduced 1995. | |
| SN | Substances that alter the body's response to an AOD substance, making ingestion of the substance unpleasant or toxic. | |
| ST | AOD aversive agents | |
| AOD sensitizing agents | ||
| NT | +YP4.8.8e alcohol deterrents qh ah | |
| YP6.8.6 sedative-hypnotic deterrents qh ah | ||
| YP8.8.8 nicotine deterrents qh ah | ||
| YP10.8.8 cocaine deterrents qh ah | ||
| YP12.8.8 opiate deterrents qh ah |
| YP2.8.10 | . . . conditioned AOD aversion agents qh |
| HN | Introduced 1995. | |
| SN | Substances that have unpleasant effects and are given together with an AOD substance. | |
| NT | +YP4.8.10e conditioned alcohol aversion agents qh ah |
| YP2.8.12 | . . . agents for AOD-concurrent mental disorders qh |
| HN | Introduced 1995. | |
| SN | The mental disorder may be primary (i.e., preexisting and underlying AOD abuse) or secondary (i.e., induced by AOD abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| ST | agents for mental disorder leading to AOD abuse | |
| agents for mental disorder resulting from AOD abuse | ||
| NT | +YP4.8.12e agents for alcohol-concurrent mental disorders qh ah | |
| +YP6.8.8 agents for sedative-hypnotic-concurrent mental disorders qh ah | ||
| YP8.8.10 agents for nicotine-concurrent mental disorders qh ah | ||
| +YP10.8.10 agents for cocaine-concurrent mental disorders qh ah | ||
| +YP12.8.10 agents for opiate-concurrent mental disorders qh ah | ||
| RT | +YP2.6e AOD withdrawal agents qh ah |
| YP2.8.12.2 | . . . . agents for AOD-concurrent depression qh |
| HN | Introduced 1995. | |
| NT | +YP4.8.12.6 agents for alcohol-concurrent depression qh ah | |
| YP6.8.8.2 agents for sedative-hypnotic-concurrent depression qh ah | ||
| +YP10.8.10.2 agents for cocaine-concurrent depression qh ah | ||
| YP12.8.10.2 agents for opiate-concurrent depression qh ah | ||
| YW6.2.2e tianeptine qh ah | ||
| BT | +YW6e antidepressants qh ah |
| YP2.8.12.4 | . . . . agents for AOD-concurrent anxiety qh |
| HN | Introduced 1995. | |
| NT | +YP4.8.12.8 agents for alcohol-concurrent anxiety qh ah | |
| YP6.8.8.4 agents for sedative-hypnotic-concurrent anxiety qh ah | ||
| +YP10.8.10.4 agents for cocaine-concurrent anxiety qh ah | ||
| YP12.8.10.4 agents for opiate-concurrent anxiety qh ah | ||
| BT | +YW4.10e tranquilizers qh ah |
| YP2.8.12.6 | . . . . agents for AOD-related cognitive impairment qh |
| HN | Introduced 1995. | |
| NT | +YP4.8.12.10 agents for alcohol-related cognitive impairment qh ah | |
| YP6.8.8.6 agents for sedative-hypnotic-related cognitive impairment qh ah | ||
| +YP10.8.10.6 agents for cocaine-related cognitive impairment qh ah | ||
| YP12.8.10.6 agents for opiate-related cognitive impairment qh ah |
| YP4e | . anti-alcohol-abuse agents qh |
| HN | ETOH descriptor 2000. | |
| ST | pharmacologic agents for alcoholism treatment |
| YP4.2e | . . anti-alcohol-intoxication agents qh |
| ST | amethystic agents | |
| NT | +YH2.4.32e vasopressin qh ah | |
| ZJ2.6.8e ibuprofen qh ah | ||
| +ZJ2.6.10.4.4.2.2e disulfiram qh ah | ||
| ZN2.12e fluvoxamine qh ah | ||
| ZQ4.6.4e naloxone qh ah | ||
| ZT4.6.6e atipamezole qh ah | ||
| ZT6.8.2.2.2.2e daidzin qh ah | ||
| ZT6.8.2.2.2.4e puerarin qh ah | ||
| BT | +YP2.2e anti-AOD-intoxication agents qh ah | |
| RT | +YL2.4 ethanol antagonists qh ah |
| YP4.4e | . . alcohol detoxification agents qh |
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP4.6e | . . alcohol withdrawal agents qh |
| SN | Agents for the treatment of acute alcohol withdrawal and its symptoms, including substances tested for alleviation of hangover (e.g., pyritinol). Protracted withdrawal may cause mental/psychiatric symptoms or lead to the reemergence of preexisting mental disorders that must be treated; see agents for alcohol concurrent mental disorders. | |
| NT | ZA2.4.2.2e lithium qh ah | |
| ZC12.8.10e nitrous oxide qh ah | ||
| ZF2.4.2.4 chloral hydrate qh ah | ||
| ZF4.2e caroverine qh ah | ||
| ZP8.4e bromocriptine qh ah | ||
| ZP32.2e apomorphine qh ah | ||
| ZT4.6.4e chlormethiazole qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| +ZT4.26.2.6e dihydropyridine qh ah | ||
| ZT4.26.2.10e nifedipine qh ah | ||
| ZT4.26.12e pyrithioxin qh ah | ||
| +ZT4.28.6.6e barbiturates qh ah | ||
| ZT4.28.6.6.12e phenobarbital qh ah | ||
| +ZT8.4.2e carbamazepine qh ah | ||
| BT | +YP2.6e AOD withdrawal agents qh ah | |
| RT | +YP4.8.2e anti-alcohol-craving agents qh ah | |
| +YT8.14e calcium channel blockers qh ah | ||
| +YV14.2.2e alpha-adrenergic receptor agonists qh ah |
| YP4.6.2e | . . . lofexidine qh |
| HN | ETOH descriptor 2000. |
| YP4.6.4e | . . . slumazenil qh |
| HN | ETOH descriptor 2000. |
| YP4.6.6 | . . . beta blockers for alcohol withdrawal qh |
| NT | ZN2.16.2.12.4.2e propranolol qh ah | |
| ZN2.16.2.18e atenolol qh ah |
| YP4.6.8e | . . . benzodiazepines for alcohol withdrawal qh |
| HN | ETOH descriptor 2000. | |
| NT | ZT6.4.2.2e alprazolam qh ah | |
| ZT6.4.2.8.8e clonazepam qh ah | ||
| +ZT6.4.2.8.12e diazepam qh ah | ||
| ZT6.4.2.8.18e flurazepam qh ah | ||
| ZT6.4.2.8.20e lorazepam qh ah | ||
| ZT6.4.2.8.24e oxazepam qh ah | ||
| ZT6.4.2.8.28e prazepam qh ah | ||
| ZT6.4.2.8.30e temazepam qh ah | ||
| ZT6.4.2.8.32e halazepam qh ah | ||
| +ZT6.4.2.10e chlordiazepoxide qh ah | ||
| ZT6.4.2.10.2e clorazepate qh ah | ||
| BT | +ZT6.4.2e benzodiazepines qh ah |
| YP4.6.10 | . . . anti-alcohol-related-delirium agents qh |
| NT | ZG4.4.2e haloperidol qh ah |
| YP4.6.12 | . . . anti-alcohol-related-seizures agents qh |
| NT | ZG8.4.4e valproic acid qh ah | |
| ZT4.14.6.2e phenytoin qh ah | ||
| ZT4.28.6.6.12e phenobarbital qh ah | ||
| +ZT8.4.2e carbamazepine qh ah |
| YP4.8e | . . alcohol relapse prevention agents qh |
| ST | alcohol dependent maintenance agents | |
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP4.8.2e | . . . anti-alcohol-craving agents qh |
| ST | alcohol intake reduction agents | |
| anti-dipsotropic agents | ||
| NT | YH2.2.2e melatonin qh ah | |
| ZT6.8.2.2.2.2e daidzin qh ah | ||
| ZT6.8.2.2.2.4e puerarin qh ah | ||
| BT | +YP2.8.2e anti-AOD-craving agents qh ah | |
| RT | +YP4.6e alcohol withdrawal agents qh ah |
| YP4.8.2.2e | . . . . serotonergic anti-alcohol-craving agents qh |
| HN | ETOH descriptor 2000. | |
| NT | +YV6.6.2e serotonin uptake inhibitors qh ah | |
| YV6.6.2.2 viqualine qh ah | ||
| ZF8.6.2.2.2e sertraline qh ah | ||
| ZN2.4.2e fluoxetine qh ah | ||
| ZN2.4.4e citalopram qh ah | ||
| ZN2.12e fluvoxamine qh ah | ||
| +ZT4.26.4.2.2e zimelidine qh ah | ||
| ZT4.26.4.2.2.2e norzimelidine qh ah | ||
| ZT4.28.2e buspirone qh ah |
| YP4.8.2.2.2e | . . . . . alaproclate qh |
| HN | ETOH descriptor 2000. |
| YP4.8.2.2.4e | . . . . . femoxetine qh |
| HN | ETOH descriptor 2000. |
| YP4.8.2.2.6e | . . . . . indalpine qh |
| HN | ETOH descriptor 2000. |
| YP4.8.2.4 | . . . . dopaminergic anti-alcohol-craving agents qh |
| NT | ZP8.4e bromocriptine qh ah |
| YP4.8.2.6 | . . . . GABA receptor agonist anti-alcohol-craving agents qh |
| NT | ZJ2.10.4.2e gamma-hydroxybutyric acid qh ah | |
| ZJ2.10.8.2.2.2.2e calcium acetylhomotaurinate qh ah | ||
| ZJ2.10.8.2.2.2.4e bis acetyl homotaurine qh ah |
| YP4.8.2.8 | . . . . narcotic antagonist anti-alcohol-craving agents qh |
| NT | ZQ4.6.4e naloxone qh ah | |
| ZQ4.6.6e naltrexone qh ah | ||
| ZQ4.8.6e nalmefene qh ah | ||
| ZT4.14.10 ondansetron qh ah |
| YP4.8.2.10 | . . . . neuropeptide anti-alcohol-craving agents qh |
| NT | YH2.4.2e thyrotropin RH qh ah | |
| YH2.4.14e adrenocorticotropic hormone qh ah | ||
| +YH2.4.32e vasopressin qh ah | ||
| YH2.4.36e cholecystokinin qh ah | ||
| YV6.6.2.4 amterozide qh ah | ||
| ZT4.28.6.4e ritanserin qh ah | ||
| BT | +ZO4.24e neuropeptides qh ah |
| YP4.8.4 | . . . alcohol agonist maintenance agents qh |
| BT | +YP2.8.4 AOD agonist maintenance agents qh ah |
| YP4.8.6e | . . . alcohol blockers qh |
| HN | ETOH descriptor 2000. | |
| ST | alcohol antagonists | |
| NT | ZQ4.6.6e naltrexone qh ah | |
| BT | +YP2.8.6 AOD blockers qh ah |
| YP4.8.8e | . . . alcohol deterrents qh |
| HN | ETOH descriptor 2000. | |
| SN | Substances that alter the body's response to alcohol, making its ingestion unpleasant or toxic. | |
| ST | alcohol aversive agents | |
| alcohol sensitizing agents | ||
| antidipsotropic agents | ||
| NT | ZC12.6.2.2e citrated calcium carbimide qh ah | |
| +ZJ2.6.10.4.4.2.2e disulfiram qh ah | ||
| ZT4.6.8e nitrefazole qh ah | ||
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP4.8.10e | . . . conditioned alcohol aversion agents qh |
| HN | ETOH descriptor 2000. | |
| SN | Substances that have unpleasant effects and are given together with alcohol. | |
| NT | +ZN2.16.2.10.2e succinylcholine qh ah | |
| ZP32.2e apomorphine qh ah | ||
| ZT6.12.2e emetine qh ah | ||
| BT | +YP2.8.10 conditioned AOD aversion agents qh ah |
| YP4.8.12e | . . . agents for alcohol-concurrent mental disorders qh |
| HN | ETOH descriptor 2000. | |
| SN | The mental disorder may be primary (i.e., preexisting and underlying alcohol abuse) or secondary (i.e., induced by alcohol abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP4.8.12.2 | . . . . dopaminergic blockers for alcohol-concurrent mental disorders qh |
| NT | ZN2.20.6.4e tiapride qh ah | |
| ZT8.14.12e thioridazine qh ah |
| YP4.8.12.4 | . . . . dopaminergic agonists for alcohol-concurrent mental disorders qh |
| NT | ZP8.4e bromocriptine qh ah | |
| ZP32.2e apomorphine qh ah |
| YP4.8.12.6 | . . . . agents for alcohol-concurrent depression qh |
| NT | +YV6.6.2e serotonin uptake inhibitors qh ah | |
| +YW6.4e MAO inhibitors qh ah | ||
| ZA2.4.2.2e lithium qh ah | ||
| ZF8.10.2.2e amitriptyline qh ah | ||
| ZN2.4.2e fluoxetine qh ah | ||
| ZT8.2.2.4e imipramine qh ah | ||
| ZT8.2.2.6e desipramine qh ah | ||
| ZT8.8.2e doxepin qh ah | ||
| BT | +YP2.8.12.2 agents for AOD-concurrent depression qh ah | |
| +YW6e antidepressants qh ah |
| YP4.8.12.8 | . . . . agents for alcohol-concurrent anxiety qh |
| NT | YW6.4.2 phenelzine qh ah | |
| ZN2.16.2.12.4.2e propranolol qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| ZT4.28.2e buspirone qh ah | ||
| +ZT6.4.2e benzodiazepines qh ah | ||
| ZT6.4.2.2e alprazolam qh ah | ||
| ZT8.2.2.4e imipramine qh ah | ||
| BT | +YP2.8.12.4 agents for AOD-concurrent anxiety qh ah | |
| +YW4.10e tranquilizers qh ah |
| YP4.8.12.10 | . . . . agents for alcohol-related cognitive impairment qh |
| NT | +YV6.6.2e serotonin uptake inhibitors qh ah | |
| ZN2.12e fluvoxamine qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| BT | +YP2.8.12.6 agents for AOD-related cognitive impairment qh ah |
| YP4.8.12.10.2 | . . . . . piridoxilate qh |
| YP6 | . anti-sedative-hypnotic-abuse agents qh |
| SN | Agents mentioned here may also apply to alcohol dependence. |
| YP6.2 | . . anti-sedative-hypnotic-intoxication agents qh |
| BT | +YP2.2e anti-AOD-intoxication agents qh ah |
| YP6.4 | . . sedative-hypnotic detoxification agents qh |
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP6.6 | . . sedative-hypnotic withdrawal agents qh |
| SN | Agents for the treatment of acute sedative-hypnotic withdrawal. Protracted withdrawal may cause mental/psychiatric symptoms that must be treated, see *+YP6.8.8 agents for sedative-hypnotic-concurrent mental disorders* qh ah. | |
| BT | +YP2.6e AOD withdrawal agents qh ah |
| YP6.6.2 | . . . barbiturate withdrawal agents qh |
| NT | ZT4.28.6.6.10e pentobarbital qh ah | |
| ZT4.28.6.6.12e phenobarbital qh ah |
| YP6.6.4 | . . . benzodiazepine withdrawal agents qh |
| NT | +ZT6.4.2.8.12e diazepam qh ah |
| YP6.8 | . . sedative-hypnotic relapse prevention agents qh |
| ST | sedative-hypnotic dependent maintenance agents | |
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP6.8.2 | . . . anti-sedative-hypnotic-craving agents qh |
| ST | sedative-hypnotic intake reduction agents | |
| BT | +YP2.8.2e anti-AOD-craving agents qh ah |
| YP6.8.4 | . . . sedative-hypnotic blockers qh |
| SN | Agents that block the mood-altering or analgesic effects of sedative-hypnotics. | |
| BT | +YP2.8.6 AOD blockers qh ah |
| YP6.8.6 | . . . sedative-hypnotic deterrents qh |
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP6.8.8 | . . . agents for sedative-hypnotic-concurrent mental disorders qh |
| SN | The mental disorder may be primary (i.e., preexisting and underlying sedative-hypnotic abuse) or secondary (i.e., induced by sedative-hypnotic abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP6.8.8.2 | . . . . agents for sedative-hypnotic-concurrent depression qh |
| BT | +YP2.8.12.2 agents for AOD-concurrent depression qh ah | |
| +YW6e antidepressants qh ah |
| YP6.8.8.4 | . . . . agents for sedative-hypnotic-concurrent anxiety qh |
| BT | +YP2.8.12.4 agents for AOD-concurrent anxiety qh ah | |
| +YW4.10e tranquilizers qh ah |
| YP6.8.8.6 | . . . . agents for sedative-hypnotic-related cognitive impairment qh |
| BT | +YP2.8.12.6 agents for AOD-related cognitive impairment qh ah |
| YP8 | . anti-nicotine-abuse agents qh |
| NT | ZT4.14.2e clonidine qh ah |
| YP8.2 | . . busprione qh |
| YP8.4 | . . nicotine detoxification agent qh |
| ST | nicotine substitution agents | |
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP8.4.2 | . . . nicotin gum qh |
| YP8.6 | . . nicotine withdrawal agents qh |
| SN | Agents for the treatment of acute nicotine withdrawal. Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see agents for nicotine concurrent mental disorders. | |
| BT | +YP2.6e AOD withdrawal agents qh ah | |
| RT | YP8.8.2 anti-nicotine-craving agents qh ah |
| YP8.8 | . . nicotine relapse prevention agents qh |
| ST | nicotine dependent maintenance agents | |
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP8.8.2 | . . . anti-nicotine-craving agents qh |
| ST | nicotine intake reduction agents | |
| BT | +YP2.8.2e anti-AOD-craving agents qh ah | |
| RT | YP8.6 nicotine withdrawal agents qh ah |
| YP8.8.4 | . . . nicotine agonist maintenance agents qh |
| BT | +YP2.8.4 AOD agonist maintenance agents qh ah |
| YP8.8.6 | . . . nicotine blockers qh |
| SN | Agents that block the mood-altering or analgesic effects of nicotine. | |
| ST | nicotine antagonist maintenance agents | |
| NT | ZU6.2e mecamylamine qh ah | |
| BT | +YP2.8.6 AOD blockers qh ah |
| YP8.8.8 | . . . nicotine deterrents qh |
| ST | nicotine aversive agents | |
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP8.8.10 | . . . agents for nicotine-concurrent mental disorders qh |
| SN | The mental disorder may be primary (i.e., preexisting and underlying nicotine abuse) or secondary (i.e., induced by nicotine abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP10 | . anti-cocaine-abuse agents qh |
| YP10.2 | . . anti-cocaine-intoxication agents qh |
| BT | +YP2.2e anti-AOD-intoxication agents qh ah |
| YP10.4 | . . cocaine detoxification agents qh |
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP10.6 | . . cocaine withdrawal agents qh |
| SN | Agents for the treatment of acute cocaine withdrawal. Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see agents for cocaine concurrent mental disorders. | |
| BT | +YP2.6e AOD withdrawal agents qh ah | |
| RT | +YP10.8.2 anti-cocaine-craving agents qh ah |
| YP10.8 | . . cocaine relapse prevention agents qh |
| ST | cocaine dependent maintenance agents | |
| NT | ZQ6.2e buprenorphine qh ah | |
| +ZT8.4.2e carbamazepine qh ah | ||
| ZT8.16.2.2e flupenthixol qh ah | ||
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP10.8.2 | . . . anti-cocaine-craving agents qh |
| NT | ZF8.2 amantadine qh ah | |
| +ZO2e amino acids qh ah | ||
| ZO2.2.2.14e tryptophan qh ah | ||
| ZO2.2.4.10e tyrosine qh ah | ||
| ZT6.4.2.6e carbamazepin qh ah | ||
| ZT8.2.2.6e desipramine qh ah | ||
| ZT8.16.2.2e flupenthixol qh ah | ||
| BT | +YP2.8.2e anti-AOD-craving agents qh ah | |
| RT | YP10.6 cocaine withdrawal agents qh ah |
| YP10.8.2.2 | . . . . bupropion qh |
| YP10.8.4 | . . . cocaine agonist maintenance agents qh |
| BT | +YP2.8.4 AOD agonist maintenance agents qh ah |
| YP10.8.6 | . . . cocaine blockers qh |
| SN | Agents that block the mood-altering or analgesic effects of cocaine. | |
| ST | cocaine antagonist maintenance agents | |
| NT | ZG4.4.2e haloperidol qh ah | |
| ZP8.4e bromocriptine qh ah | ||
| ZT4.18.4e trazodone qh ah | ||
| ZT8.2.2.4e imipramine qh ah | ||
| BT | +YP2.8.6 AOD blockers qh ah | |
| RT | +YV6 neuroregulator blockaders qh ah |
| YP10.8.8 | . . . cocaine deterrents qh |
| ST | cocaine aversive agents | |
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP10.8.10 | . . . agents for cocaine-concurrent mental disorders qh |
| SN | The mental disorder may be primary (i.e., preexisting and underlying cocaine abuse) or secondary (i.e., induced by cocaine abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| NT | ZJ2.4e methylphenydate qh ah | |
| ZT4.16.4.2e magnesium pemoline qh ah | ||
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP10.8.10.2 | . . . . agents for cocaine-concurrent depression qh |
| NT | ZF8.4 maprotiline qh ah | |
| ZT4.18.4e trazodone qh ah | ||
| ZT8.2.2.4e imipramine qh ah | ||
| ZT8.2.2.6e desipramine qh ah | ||
| ZT8.8.2e doxepin qh ah | ||
| BT | +YP2.8.12.2 agents for AOD-concurrent depression qh ah | |
| +YW6e antidepressants qh ah |
| YP10.8.10.4 | . . . . agents for cocaine-concurrent anxiety qh |
| NT | ZT8.2.2.6e desipramine qh ah | |
| BT | +YP2.8.12.4 agents for AOD-concurrent anxiety qh ah | |
| +YW4.10e tranquilizers qh ah |
| YP10.8.10.6 | . . . . agents for cocaine-related cognitive impairment qh |
| SN | *GZ12.2.2 attention deficit disorder with hyperactivity* qh ah in particular is associated with cocaine abuse. | |
| NT | ZJ2.10.4.8e methylphenidate qh ah | |
| ZT4.16.4.2e magnesium pemoline qh ah | ||
| BT | +YP2.8.12.6 agents for AOD-related cognitive impairment qh ah |
| YP12 | . anti-opiate-abuse agents qh |
| YP12.2 | . . anti opiate intoxication agents qh |
| NT | ZQ4.6.4e naloxone qh ah | |
| BT | +YP2.2e anti-AOD-intoxication agents qh ah |
| YP12.4 | . . opiate detoxification agents qh |
| NT | ZQ4.6.6e naltrexone qh ah | |
| +ZQ10.2e methadone qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP12.6 | . . opiate withdrawal agents qh |
| SN | Agents for the treatment of acute opiate withdrawal. Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see agents for opiate concurrent mental disorders. | |
| NT | +ZQ10.2e methadone qh ah | |
| ZT4.14.2e clonidine qh ah | ||
| BT | +YP2.6e AOD withdrawal agents qh ah | |
| RT | YP12.8.2 anti-opiate-craving agents qh ah |
| YP12.8 | . . opiate relapse prevention agents qh |
| ST | opiate dependent maintenance agents | |
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP12.8.2 | . . . anti-opiate-craving agents qh |
| ST | opiate intake reduction agents | |
| BT | +YP2.8.2e anti-AOD-craving agents qh ah | |
| RT | +YP12.6 opiate withdrawal agents qh ah | |
| +YP12.8.4 opiate agonist maintenance agents qh ah | ||
| +YP12.8.6 opiate blockers qh ah |
| YP12.8.4 | . . . opiate agonist maintenance agents qh |
| NT | ZQ6.2e buprenorphine qh ah | |
| +ZQ10.2e methadone qh ah | ||
| ZQ10.4e LAAM qh ah | ||
| BT | +YP2.8.4 AOD agonist maintenance agents qh ah | |
| RT | YP12.8.2 anti-opiate-craving agents qh ah |
| YP12.8.6 | . . . opiate blockers qh |
| SN | Agents that block the mood-altering or analgesic effects of opiates. | |
| ST | opiate antagonist maintenance agents | |
| NT | ZQ4.6.6e naltrexone qh ah | |
| BT | +YP2.8.6 AOD blockers qh ah | |
| RT | YP12.8.2 anti-opiate-craving agents qh ah |
| YP12.8.8 | . . . opiate deterrents qh |
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP12.8.10 | . . . agents for opiate-concurrent mental disorders qh |
| SN | The mental disorder may be primary (i.e., preexisting and underlying opiate abuse) or secondary (i.e., induced by opiate abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP12.8.10.2 | . . . . agents for opiate-concurrent depression qh |
| BT | +YP2.8.12.2 agents for AOD-concurrent depression qh ah | |
| +YW6e antidepressants qh ah |
| YP12.8.10.4 | . . . . agents for opiate-concurrent anxiety qh |
| BT | +YP2.8.12.4 agents for AOD-concurrent anxiety qh ah | |
| +YW4.10e tranquilizers qh ah |
| YP12.8.10.6 | . . . . agents for opiate-related cognitive impairment qh |
| BT | +YP2.8.12.6 agents for AOD-related cognitive impairment qh ah |
| YQ | anti-inflammatory, anti-infective, and antineoplastic agents d-out qh |
| BT | +YNe therapeutic agents qh ah |
| YQ2e | . anti-inflammatory agents qh |
| ST | tissue protective agents | |
| tissue repair agents | ||
| NT | ZN2.18.2.2.2.2.2e R alpha methylhistamine qh ah |
| YQ2.2 | . . nonsteroidal anti-inflammatory drugs qh |
| ST | NSAID | |
| NT | +YR2.2.6 gout suppressants qh ah | |
| +ZJ2.10.10.2.4.2.4e salicylate qh ah | ||
| ZT4.24.4e antipyrine qh ah | ||
| ZT4.30.12e tolmetin qh ah | ||
| ZT4.34.2e piroxicam qh ah | ||
| ZT6.10.6e indomethacin qh ah |
| YQ2.4 | . . steroidal anti-inflammatory drugs qh |
| NT | YH4.6.2.2e dexamethasone qh ah | |
| ZV8.2.2.2e prednisone qh ah | ||
| ZV8.2.4.2e prednisolone qh ah | ||
| RT | +ZVe steroids qh ah |
| YQ4e | . anti-infective agents qh |
| NT | +YT12.2 urinary anti-infective agents qh ah | |
| +ZN2.20.8e sulfonamide qh ah |
| YQ4.2 | . . local anti-infective agents qh |
| NT | ZJ2.6.10.4.4.4.2e thiram qh ah |
| YQ4.4 | . . antitubercular agents qh |
| NT | ZF6.6e isoniazid qh ah | |
| RT | +GH16.14.4.2e tuberculosis qh ah |
| YQ4.6 | . . antibacterial agents qh |
| NT | ZT6.24.2e ciprofloxacin qh ah |
| YQ4.6.2 | . . . leprostatic agents qh |
| NT | YQ4.14.16.2 rifampin qh ah | |
| ZJ2.10.10.6.2.2e thalidomide qh ah | ||
| RT | GH16.14.4.4 Hansen's disease qh ah |
| YQ4.8 | . . antifungal agents qh |
| NT | +YQ4.14.6 antifungal antibiotics qh ah | |
| ZJ2.6.10.4.4.4.2e thiram qh ah |
| YQ4.10 | . . antiparasitic agents qh |
| NT | ZT4.32.4e kainate qh ah |
| YQ4.10.2 | . . . anthelmintics qh |
| YQ4.10.4 | . . . antiprotozoal agents qh |
| YQ4.10.4.2 | . . . . antimalarials qh |
| NT | ZP4.4e quinine qh ah | |
| ZT4.28.4e pyrimethamine qh ah | ||
| ZT8.2.2.2e quinacrine qh ah |
| YQ4.12 | . . antiviral agents qh |
| NT | YE10.8.4e interferon qh ah |
| YQ4.12.2 | . . . acyclovir qh |
| YQ4.14e | . . antibiotics qh |
| NT | YD8.12.2e ionophores qh ah | |
| ZF2.4.2.8.2e chloramphenicol qh ah |
| YQ4.14.2 | . . . aminoglycoside antibiotics qh |
| NT | +ZG8.2.2.2e gentamicin qh ah | |
| ZG8.2.2.4e neomycin qh ah |
| YQ4.14.4 | . . . antitubercular antibiotics qh |
| NT | YQ4.14.16.2 rifampin qh ah |
| YQ4.14.6 | . . . antifungal antibiotics qh |
| NT | ZT4.20.8.2e cycloheximide qh ah | |
| BT | +YQ4.8 antifungal agents qh ah |
| YQ4.14.6.2 | . . . . griseofulvin qh |
| BT | +YD8.2 ADH antagonists qh ah |
| YQ4.14.6.4 | . . . . nystatin qh |
| YQ4.14.8 | . . . antineoplastic antibiotics qh |
| BT | +YQ6 antineoplastic agents qh ah |
| YQ4.14.10 | . . . lactam antibiotics qh |
| YQ4.14.10.2 | . . . . moxalactam qh |
| YQ4.14.10.4 | . . . . penicillin qh |
| YQ4.14.10.4.2 | . . . . . penicillin G qh |
| ST | penicillin G benzathine | |
| penicillin G procaine |
| YQ4.14.12 | . . . macrolide antibiotics qh |
| YQ4.14.12.2 | . . . . amphotericin qh |
| YQ4.14.12.4 | . . . . erythromycin qh |
| YQ4.14.14 | . . . bacitracin qh |
| YQ4.14.16 | . . . rifamycins qh |
| YQ4.14.16.2 | . . . . rifampin qh |
| BT | +YQ4.6.2 leprostatic agents qh ah | |
| +YQ4.14.4 antitubercular antibiotics qh ah |
| YQ4.14.18e | . . . tetracyclines qh |
| HN | ETOH descriptor 2000. |
| YQ4.14.20 | . . . combined antibiotics qh |
| YQ6 | . antineoplastic agents qh |
| ST | anti-neoplastic agents | |
| NT | YQ4.14.8 antineoplastic antibiotics qh ah | |
| ZJ2.6.10.4.6e urethane qh ah | ||
| ZN2.20.6.8e procarbazine qh ah | ||
| ZT8.2.2.2e quinacrine qh ah | ||
| ZV8.2.2.2e prednisone qh ah | ||
| RT | YE12e immunosuppressive agents qh ah |
| YR | analgesics and anesthetics d-out qh |